TY - JOUR
T1 - 177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer
AU - Parihar, Ashwin Singh
AU - Hofman, Michael S.
AU - Iravani Tabrizipour, Amir
N1 - Publisher Copyright:
© RSNA, 2022.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - A 76-year-old man with metastatic castration-resistant prostate carcinoma progressing with antiandrogen and taxane therapy was treated with lutetium 177 prostate-specific membrane antigen (PSMA)-617 and showed marked biochemical and imaging response, with improvement in clinical status and osseous pain. A summary of nuclear medicine theranostics with emphasis on PSMA targeting agents is presented.
AB - A 76-year-old man with metastatic castration-resistant prostate carcinoma progressing with antiandrogen and taxane therapy was treated with lutetium 177 prostate-specific membrane antigen (PSMA)-617 and showed marked biochemical and imaging response, with improvement in clinical status and osseous pain. A summary of nuclear medicine theranostics with emphasis on PSMA targeting agents is presented.
UR - http://www.scopus.com/inward/record.url?scp=85147047714&partnerID=8YFLogxK
U2 - 10.1148/radiol.220859
DO - 10.1148/radiol.220859
M3 - Article
C2 - 36125377
AN - SCOPUS:85147047714
SN - 0033-8419
VL - 306
SP - e220859
JO - Radiology
JF - Radiology
IS - 2
ER -